title: Blood-derived topical therapy for ocular surface diseases.
abstract: Human serum-derived and plasma-derived therapies have become increasingly popular in the treatment of ocular surface disorders, with mounting clinical and scientific evidence suggesting good safety and efficacy profiles. These therapies may be considered for various ocular surface conditions, such as dry eye syndrome and persistent epithelial defect, when conservative management does not suffice. The costly and inconvenient process of obtaining the blood-derived products is the barrier to their more widespread use. Some blood-derived therapies, such as umbilical cord serum-derived and platelet-derived plasma preparations, may be more viable options since these therapies can be made readily available to patients. In this review, the existing literature on the safety and efficacy of blood-derived products, such as autologous serum tears, in the treatment of ocular surface diseases is discussed. Issues relevant to the production of autologous serum tears are also described.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Nishant G
authors.initials: NG
authors.lastname: Soni
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Bennie H
authors.initials: BH
authors.lastname: Jeng
mesh_terms: D000287:Administration, Topical; D003316:Corneal Diseases / Q000628:therapy*; D015352:Dry Eye Syndromes / Q000628:therapy*; D005312:Fetal Blood; D006801:Humans; D009883:Ophthalmic Solutions; D010949:Plasma; D053657:Platelet-Rich Plasma; D044967:Serum
chemical_list: D009883:Ophthalmic Solutions
keywords: Cornea; Ocular surface; Tears